Teva closes BioXcel asset purchase in bankruptcy proceeding
Teva Pharmaceuticals completed its purchase of BioXcel Therapeutics' neuroscience assets on October 27, 2026. The transaction includes BXCL501, an investigational sublingual dexmedetomidine film under U.S. FDA review for acute agitation linked to schizophrenia or bipolar disorder, and Igalmi, an FDA-cleared hospital treatment. Contract Pharma reports an upfront payment of $57.5 million, with total consideration potentially reaching $67.5 million through contingent payments.
Why it matters
The deal gives Teva additional neuroscience assets, including a candidate that could enable treatment outside hospitals if approved for that use. Teva described BXCL501 as a strategic match for its neuroscience portfolio and said the assets target unmet patient needs.
Key facts
- 1Teva acquired BioXcel Therapeutics' assets for $57.5 million initially, with contingent payments bringing the possible total to $67.5 million. contractpharma.com
- 2The acquired portfolio includes BXCL501, which is under U.S. FDA review for acute agitation associated with schizophrenia or bipolar I or II disorder. contractpharma.com
- 3Igalmi, another acquired asset, is FDA-approved for use in a hospital setting for the same indications. contractpharma.com
- 4BioXcel Therapeutics and its subsidiaries entered Chapter 11 proceedings after the asset sale agreement became public in August 2026. contractpharma.com
Open questions
- Material 2 says the financial terms were not disclosed, conflicting with material 1's reported $57.5 million upfront payment and possible total of $67.5 million.
- BXCL501 remains under FDA review, so its potential at-home use has not yet received regulatory approval.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.